Clonally expanded CD8 T cells characterize amyotrophic lateral sclerosis-4

Amyotrophic lateral sclerosis (ALS) is a heterogenous neurodegenerative disorder that affects motor neurons and voluntary muscle control 1 . ALS heterogeneity includes the age of manifestation, the rate of progression and the anatomical sites of symptom onset. Disease-causing mutations in specific g...

Full description

Saved in:
Bibliographic Details
Published in:Nature (London) Vol. 606; no. 7916; pp. 945 - 952
Main Authors: Campisi, Laura, Chizari, Shahab, Ho, Jessica S. Y., Gromova, Anastasia, Arnold, Frederick J., Mosca, Lorena, Mei, Xueyan, Fstkchyan, Yesai, Torre, Denis, Beharry, Cindy, Garcia-Forn, Marta, Jiménez-Alcázar, Miguel, Korobeynikov, Vladislav A., Prazich, Jack, Fayad, Zahi A., Seldin, Marcus M., De Rubeis, Silvia, Bennett, Craig L., Ostrow, Lyle W., Lunetta, Christian, Squatrito, Massimo, Byun, Minji, Shneider, Neil A., Jiang, Ning, La Spada, Albert R., Marazzi, Ivan
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 30-06-2022
Nature Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amyotrophic lateral sclerosis (ALS) is a heterogenous neurodegenerative disorder that affects motor neurons and voluntary muscle control 1 . ALS heterogeneity includes the age of manifestation, the rate of progression and the anatomical sites of symptom onset. Disease-causing mutations in specific genes have been identified and define different subtypes of ALS 1 . Although several ALS-associated genes have been shown to affect immune functions 2 , whether specific immune features account for ALS heterogeneity is poorly understood. Amyotrophic lateral sclerosis-4 (ALS4) is characterized by juvenile onset and slow progression 3 . Patients with ALS4 show motor difficulties by the time that they are in their thirties, and most of them require devices to assist with walking by their fifties. ALS4 is caused by mutations in the senataxin gene ( SETX ). Here, using Setx knock-in mice that carry the ALS4-causative L389S mutation, we describe an immunological signature that consists of clonally expanded, terminally differentiated effector memory (T EMRA ) CD8 T cells in the central nervous system and the blood of knock-in mice. Increased frequencies of antigen-specific CD8 T cells in knock-in mice mirror the progression of motor neuron disease and correlate with anti-glioma immunity. Furthermore, bone marrow transplantation experiments indicate that the immune system has a key role in ALS4 neurodegeneration. In patients with ALS4, clonally expanded T EMRA CD8 T cells circulate in the peripheral blood. Our results provide evidence of an antigen-specific CD8 T cell response in ALS4, which could be used to unravel disease mechanisms and as a potential biomarker of disease state. An immune signature characterized by activated antigen-specific CD8 T cells is identified in the brain and blood of mice with amyotrophic lateral sclerosis-4 (ALS4), suggesting that the immune system is involved in ALS4 neurodegeneration.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Author contributions. L.C. and I.M. conceived, designed and directed the study. S.D.R., M.B., M.M.S., M.S., L.W.O., C.L., N.A.S., N.J. and A.R.L.S. provided conceptual and experimental guidance. L.C. conducted all experiments with the assistance of A.G. and F.J.A. (histology); V.A.K. (ALS6 mouse model); L.M. (blood collection and isolation of PBMCs); J.S.Y.H., Y.F. and C.B. (mouse dissection); J.P. (mouse TCR sequencing), J.S.Y.H., M.G.-F. and M.J.-A. (tumour models); and C.L.B. (preliminary analyses on SetxL389S+/− mice). M.J.-A. and M.S. generated and provided tumour-derived NSCs (glioma model). L.C. analysed and visualized the data. S.C. performed and visualized CITE-seq and SMART-seq analyses. J.S.Y.H. and D.T. performed and visualized splicing analyses. X.M. conceived and performed the axon counting by Gaussian filters, under the supervision of Z.A.F. L.C. administered the project. I.M. acquired funding. L.C. wrote the paper with edits from I.M., A.R.L.S. and S.C., and with feedback from all of the authors.
ISSN:0028-0836
1476-4687
1476-4687
DOI:10.1038/s41586-022-04844-5